Pallas Capital Advisors LLC Fate Therapeutics Inc Transaction History
Pallas Capital Advisors LLC
- $2.24 Billion
- Q1 2025
A detailed history of Pallas Capital Advisors LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 14,232 shares of FATE stock, worth $18,216. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,232Holding current value
$18,216% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
168Shares Held
100MCall Options Held
41.3KPut Options Held
15.9K-
Redmile Group, LLC San Francisco, CA12.9MShares$16.5 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$13.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$12.9 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$6.19 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$5.61 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $124M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...